GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

As for the clinical presentation, most kids had fever (93%) and seizures (68%). They also had elevated liver enzymes (78%), ...

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 3.1% in the morning session after ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock ...

GSK gained after saying it expects to be towards the top end of its financial guidance for 2025 as it posted a 6% jump in ...

Emma Walmsley, GSK CEO, joins CNBC's 'Squawk on the Street' to discuss the company's most recent earnings, innovation ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...

GSK anticipates high sales and profit growth in 2025 after surpassing second-quarter forecasts, while addressing U.S. tariffs ...